XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.25.2

SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition | The following table presents collaboration revenue under the Janssen Collaboration Agreement for the three and six months ended June 30, 2024 (in thousands):
|  |  | Three Months Ended June 30, |  |  |  | Six Months Ended June 30,
|  |  | 2024 |  |  |  | 2024
Revenue from Janssen Collaboration Agreement: |  |  |  |  |  |  |
Over Time: |  |  |  |  |  |  |
Research and Development Services |  |  | $ | 302 |  |  |  |  | $ | 1,273 |
Clinical Supply Services |  |  | — |  |  |  |  | 2 |
Total Revenue from Janssen Collaboration Agreement |  |  | $ | 302 |  |  |  |  | $ | 1,275 |
The following table presents collaboration and product revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition, for the three and six months ended June 30, 2024 (in thousands):
| Three Months Ended June 30, 2024 |  | Six Months Ended June 30, 2024
| Mundipharma |  | Melinta |  | Mundipharma |  | Melinta
Revenue from Collaboration, License and Purchase Agreements: |  |  |  |  |  |  |
Point in Time: |  |  |  |  |  |  |
Rezafungin Assets, including Sale of Intellectual Property and Inventory | $ | 20,833 |  |  | $ | — |  |  | $ | 20,833 |  |  | $ | — |
License of Intellectual Property - upon milestone achieved | $ | — |  |  | $ | — |  |  | $ | 813 |  |  | $ | — |
Product Revenue | — |  |  | — |  |  | 2,826 |  |  | — |
Royalty Revenue | 11 |  |  | 49 |  |  | 37 |  |  | 125 |
Over Time: |  |  |  |  |  |  |
Research and Development Services | 629 |  |  | 140 |  |  | 3,895 |  |  | 457 |
Clinical Supply Services | 9 |  |  | — |  |  | 175 |  |  | — |
Transition Services | 91 |  |  | — |  |  | 91 |  |  | — |
Total Revenue from Collaboration, License and Purchase Agreements | $ | 21,573 |  |  | $ | 189 |  |  | $ | 28,670 |  |  | $ | 582 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration